{"organizations": [], "uuid": "7e8b4d99708837dd4b25a1be7a9e038f532bb5fb", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-ema-recommends-against-approval-of/brief-ema-recommends-against-approval-of-puma-biotechnologys-breast-cancer-drug-neratinib-idUSFWN1QD0MX", "country": "US", "domain_rank": 408, "title": "BRIEF-EMA Recommends Against Approval Of Puma Biotechnology's Breast Cancer Drug Neratinib‍​", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-23T14:15:00.000+02:00", "replies_count": 0, "uuid": "7e8b4d99708837dd4b25a1be7a9e038f532bb5fb"}, "author": "", "url": "https://www.reuters.com/article/brief-ema-recommends-against-approval-of/brief-ema-recommends-against-approval-of-puma-biotechnologys-breast-cancer-drug-neratinib-idUSFWN1QD0MX", "ord_in_thread": 0, "title": "BRIEF-EMA Recommends Against Approval Of Puma Biotechnology's Breast Cancer Drug Neratinib‍​", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-ema recommends against approval of puma", "sentiment": "negative"}, {"name": "brief-ema recommends against approval of puma biotechnology", "sentiment": "negative"}, {"name": "eu medicines agency", "sentiment": "none"}, {"name": "eu", "sentiment": "none"}, {"name": "pfizer", "sentiment": "none"}, {"name": "breast cancer drug neratinib‍​ reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 23, 2018 / 12:15 PM / Updated 10 minutes ago BRIEF-EMA Recommends Against Approval Of Puma Biotechnology's Breast Cancer Drug Neratinib‍​ Reuters Staff Feb 23 (Reuters) - EU Medicines Agency: * EU MEDICINES AGENCY RECOMMENDATIONS FOR FEBRUARY 2018 * EU MEDICINES AGENCY RECOMMENDATIONS FOR FEBRUARY 2018 BREAST CANCER DRUG NERATINIB * EU MEDICINES AGENCY RECOMMENDS APPROVAL OF PFIZER'S MYLOTARG FOR TREATMENT OF ACUTE MYELOID LEUKAEMIA‍​‍​‍​ Source ( bit.ly/2FtAttD ) Further company coverage:", "external_links": [], "published": "2018-02-23T14:15:00.000+02:00", "crawled": "2018-02-23T14:28:12.015+02:00", "highlightTitle": ""}